Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Operations: 2019-2024

Historic Cash from Operations for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$142.1 million.

  • Centessa Pharmaceuticals' Cash from Operations fell 172.63% to -$58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.8 million, marking a year-over-year decrease of 38.76%. This contributed to the annual value of -$142.1 million for FY2024, which is 11.40% up from last year.
  • Centessa Pharmaceuticals' Cash from Operations amounted to -$142.1 million in FY2024, which was up 11.40% from -$160.3 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Cash from Operations registered a high of -$10.6 million during FY2020, and its lowest value of -$200.5 million during FY2022.
  • In the last 3 years, Centessa Pharmaceuticals' Cash from Operations had a median value of -$160.3 million in 2023 and averaged -$167.6 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Cash from Operations crashed by 1,171.02% in 2021, and later rose by 20.05% in 2023.
  • Centessa Pharmaceuticals' Cash from Operations (Yearly) stood at -$10.6 million in 2020, then crashed by 1,171.02% to -$135.1 million in 2021, then slumped by 48.43% to -$200.5 million in 2022, then climbed by 20.05% to -$160.3 million in 2023, then rose by 11.40% to -$142.1 million in 2024.